RxGrab · Drug pricing tool · CMS NADAC and FDA Orange Book read 2026-11-12

How fast does a generic drug get cheaper after the first generic?

Two years after the first generic approval, what pharmacies pay for a generic is a median 80% of its first observed price; after five years 46%; after ten 22%. That is the median of 200 matched tablet and capsule generics, and the spread is wide: after ten years the middle half runs from 5% to 53%. It is a pattern in acquisition cost, not what you pay, and it does not say the first generic caused the fall.

Try one

0%25%50%75%100%0 years after the first generic approval: median 100%, middle half 100% to 100%, 79 products1 years after the first generic approval: median 95%, middle half 71% to 100%, 118 products2 years after the first generic approval: median 80%, middle half 49% to 99%, 135 products3 years after the first generic approval: median 64%, middle half 36% to 90%, 142 products4 years after the first generic approval: median 55%, middle half 25% to 84%, 154 products5 years after the first generic approval: median 46%, middle half 16% to 80%, 154 products6 years after the first generic approval: median 45%, middle half 16% to 87%, 154 products7 years after the first generic approval: median 40%, middle half 14% to 71%, 153 products8 years after the first generic approval: median 32%, middle half 8% to 65%, 131 products9 years after the first generic approval: median 28%, middle half 7% to 67%, 109 products10 years after the first generic approval: median 22%, middle half 5% to 53%, 90 products11 years after the first generic approval: median 21%, middle half 5% to 51%, 79 products12 years after the first generic approval: median 16%, middle half 6% to 34%, 48 products13 years after the first generic approval: median 19%, middle half 14% to 39%, 23 products024681012years since the first generic approval
median of 200 matched productsmiddle halfeach product
Not medical or financial advice. This page reports a pattern in what pharmacies pay to acquire generic drugs. It is not what you will be charged, and it says nothing about which medicine is right for you. Ask your pharmacist or prescriber.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the CMS pharmacy pricing page year-end surveys and the Orange Book data files, read 2026-11-12.

How do you read the cliff?

You read the cliff as a median with a wide band around it, not as a rule.

  1. Year zero is the year the first generic in the drug's Orange Book group was approved.
  2. Each line is one product's year-end acquisition cost divided by its first observed year-end price, so every line starts at 100%.
  3. The heavy line is the median across products, and the shaded band is the middle half of them.
  4. Add a drug to see where its own line sits against the band.
  5. Take it to your pharmacist: acquisition cost is not your price.

What does the curve look like year by year?

The median generic keeps getting cheaper for about ten years after the first generic approval, fastest in the first five.

Years since first generic approvalMedianMiddle halfProducts
0100%100% to 100%79
195%71% to 100%118
280%49% to 99%135
364%36% to 90%142
455%25% to 84%154
546%16% to 80%154
645%16% to 87%154
740%14% to 71%153
832%8% to 65%131
928%7% to 67%109
1022%5% to 53%90
1121%5% to 51%79
1216%6% to 34%48
1319%14% to 39%23

200 matched products. A year is shown only where 20 or more products contribute. Index of the year-end median per-unit acquisition cost to its first observed year-end price at or after the first generic approval.

What is the most common mistake when reading the curve?

The most common mistake reads the median as a forecast for one drug. Individual drugs sit far above and below it.

The misreading

"The curve says my generic will cost half as much in five years."

The fix

Read the band, not the line: after five years the middle half of drugs runs from 16% to 80%. Add your drug to see its own path, and see the FDA generic drug facts for how generics are approved.

Can you put the cliff on your own site?

The curve can be shown on another site as a self-sizing panel, free with the source line left in place.

<div data-generic-price-cliff></div> <script async src="https://rxgrab.com/tools/generic-price-cliff/embed.js"></script>

Questions people ask about generic prices

How fast does a generic drug get cheaper after the first generic?

Across 200 matched tablet and capsule generics, the median acquisition cost is 80% of its first observed year-end price two years after the first generic approval, 46% after five years and 22% after ten. The spread between drugs is wide: after ten years the middle half runs from 5% to 53%.

Does the first generic cause the price to fall?

This page does not say so. It describes the pattern in the matched products. Competition, supply, rebates and changes in what is priced all move acquisition costs, and the data does not separate them.

Will my drug follow the curve?

No one can say that from this page. The curve is the median of matched products and individual drugs sit far above and below it. Type your drug to see its own path beside the median.

Is this what I pay at the pharmacy?

No. NADAC is the price pharmacies pay to acquire a drug. What you pay adds a dispensing fee and margin and depends on your plan or card.

Why are only some drugs included?

A drug is included when it is a generic tablet or capsule that matches one single-ingredient Orange Book group with a dated first brand and first generic approval from 2013 to 2022, and has at least three year-end surveys after that. Injectables, liquids, combinations and older drugs are not included, so the curve describes a minority of products.

Where does the data come from?

The CMS National Average Drug Acquisition Cost year-end surveys and the FDA Orange Book data files, read 2026-11-12. Both are public US government data.

Can I put this on my own website?

Yes. The embed code on this page shows the curve as a self-sizing panel, free to use with the source line left in place.

How was the cliff built and checked?

The cliff joins two public datasets, each with its own frozen method, under a third frozen method written before any figure was published. A separate reader rebuilt the matched product set and the whole curve from the raw snapshot rows and the raw Orange Book files; its first run found a matching defect in the builder (a single-ingredient drug matched to a three-drug combination), which is recorded as a dated amendment, and after the fix the two agree on all 200 products and every year of the curve. What the independent check found. The dataset behind it is published at doi:10.5281/zenodo.24182324. Further reading: the CMS pharmacy pricing page; the CMS open data portal; the FDA Orange Book; the Orange Book data files; how generic drugs are approved; the FDA generic drug facts; the FDA first generic approvals; 42 CFR 447.512 on drug payment; the FTC on pharmaceutical competition; the Congressional Budget Office on health care; the NLM RxNav drug names service.